Evercore sees Lab Corp, Quest shares facing Medicare pricing headwind

CMS preliminary 2027 laboratory fee rates indicate Medicare has been paying about 16% above private-payor rates, triggering the maximum 15% PAMA reimbursement reduction beginning January 1, 2027 and phased through 2029. Evercore estimates a $90 million-$100 million adjusted operating-income hit in 2027 for Laboratory Corporation and Quest Diagnostics, equating to a low-to-mid-single-digit EPS impact and pushing results toward the lower end of long-term guidance ranges. Final rates are expected in November, while publicly available pricing detail is not expected until December 2026; Quest's recently raised guidance and Q2 beat partly offset the longer-dated reimbursement risk.

Analysis

The market should treat the reimbursement reset as a 2027 earnings-multiple issue rather than a near-term revenue shock. With the economic hit already incorporated into both companies’ long-term frameworks, the key variable is whether management can offset it through test mix, procurement savings, automation, and commercial pricing; failure to do so would put the lower end of guidance ranges at risk and likely cap multiple expansion through 2026. LH has partial insulation from its drug-development and specialty businesses, while DGX’s more concentrated diagnostics model offers cleaner exposure to any eventual reimbursement relief or worsening.

The underappreciated second-order risk is commercial-payor repricing. A lower Medicare benchmark can strengthen insurers’ negotiating position in the next contract cycle, creating a broader realization headwind that is not captured by a static Medicare-only earnings estimate. Conversely, the unusually limited survey participation creates a meaningful procedural-risk asymmetry: revisions, legal challenge, or a legislative delay could remove an overhang before the rate implementation date, particularly if hospital reporting quality becomes politically contested.

Near term, this is unlikely to be a high-conviction directional catalyst because final visibility is distant and the headline impact appears manageable. The more investable setup is dispersion around 2026 guidance: investors should watch organic diagnostic revenue, price versus volume contribution, and cost-savings delivery. A material cut to 2027 EPS expectations, or evidence that commercial rates follow Medicare downward, would falsify the benign interpretation; a delay or revised final schedule would reverse the bear case quickly.

Key Decisions for Investors

• Maintain a neutral-to-underweight stance on DGX and LH into 2026 guidance updates rather than initiating an outright short now; the reimbursement effect is too distant for a clean near-term catalyst. Escalate to a short bias only if either company identifies commercial-price pressure or reduces its long-term EPS algorithm.
• Prefer a relative-value long LH / short DGX position over 6-12 months if both sell off comparably on reimbursement headlines. LH’s non-diagnostics earnings streams should dilute pure reimbursement sensitivity; exit if LH’s diagnostics margin deterioration exceeds DGX’s or if drug-development demand weakens materially.
• For existing DGX longs, use any relief rally following a favorable final-rate revision or delay to reduce exposure rather than chase upside. Risk/reward becomes less attractive if valuation remains above historical diagnostics-peer multiples while 2027 EPS uncertainty persists.
• Set an event-driven alert for the final CMS release and any congressional/PAMA-related legislative action. A meaningful reduction in the implied rate cut or implementation delay would be a tactical positive for both names; confirmation of the full schedule combined with commercial repricing would favor DGX underperformance versus LH.